Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG727

—

66ed4de8-2cdd-5dcd-9deb-4535ad4f9b23

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.397
  • PROTEIN_SECRETION+0.344
  • G2M_CHECKPOINT+0.311
  • MTORC1_SIGNALING+0.269
  • UV_RESPONSE_DN+0.253
  • SPERMATOGENESIS+0.251
  • ANDROGEN_RESPONSE+0.223
  • PANCREAS_BETA_CELLS+0.215
  • HEDGEHOG_SIGNALING+0.142
  • KRAS_SIGNALING_UP+0.131

Top 10 suppressed

  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.345
  • CHOLESTEROL_HOMEOSTASIS-0.307
  • MYOGENESIS-0.284
  • WNT_BETA_CATENIN_SIGNALING-0.276
  • APICAL_JUNCTION-0.235
  • DNA_REPAIR-0.226
  • MYC_TARGETS_V2-0.218
  • UV_RESPONSE_UP-0.212
  • TNFA_SIGNALING_VIA_NFKB-0.205
  • COAGULATION-0.177

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SJEPD030795_D2.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.774
2ERR2598094
medullo-epn-umap@date-based
fetalfetal0.766
3SJEPD031786_D2.RNA-Seq
medullo-epn-umap@date-based
EPNAnaplastic EPN0.760
4MNG641
mng-umap@100
——0.754
5SRR2016942
head-neck@1
——0.734
6R322R
bladder-landscape@3
——0.714
7TCGA-AO-A1KS-01A-11R-A13Q-07
breast-umap@18
—B0.712
8ac295603-d08a-43f7-a78b-610be32aa49f
melanoma-umap@29
——0.703
9SRR12475129
colon-landscapes@1
——0.703
10MNG636
mng-umap@100
——0.695

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 19 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.397Inavolisib— uncovered
PROTEIN_SECRETION0.344Remibrutinib— uncovered
G2M_CHECKPOINT0.311Inavolisib— uncovered
MTORC1_SIGNALING0.269Inavolisib— uncovered
UV_RESPONSE_DN0.253Inavolisib— uncovered
SPERMATOGENESIS0.251Inavolisib— uncovered
ANDROGEN_RESPONSE0.223Inavolisib— uncovered
PANCREAS_BETA_CELLS0.215Cobimetinib— uncovered
HEDGEHOG_SIGNALING0.142Inavolisib— uncovered
KRAS_SIGNALING_UP0.131Inavolisib— uncovered
ALLOGRAFT_REJECTION0.107Idelalisib— uncovered
MYC_TARGETS_V10.107Inavolisib— uncovered
ANGIOGENESIS0.091Remibrutinib— uncovered
OXIDATIVE_PHOSPHORYLATION0.089Remibrutinib— uncovered
INFLAMMATORY_RESPONSE0.073Idelalisib— uncovered
NOTCH_SIGNALING0.058Inavolisib— uncovered
MITOTIC_SPINDLE0.035Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.033Idelalisib— uncovered
TGF_BETA_SIGNALING0.026Inavolisib— uncovered